Edgewise Therapeutics (EWTX) Return on Capital Employed (2021 - 2026)
Edgewise Therapeutics (EWTX) reported Return on Capital Employed of 38.9% for Q1 2026, down 107.0% on a YoY basis from 555.71% in Q1 2025, and down 9.88% sequentially from 35.4% in Q4 2025.
Edgewise Therapeutics (EWTX) Return on Capital Employed (2021 - 2026) Analysis & Trends
Edgewise Therapeutics (EWTX) has 6 years of Return on Capital Employed data on file, last reported at 38.9% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 107.0% year-over-year to 38.9%; the trailing twelve-month figure through Mar 2026 stood at 38.9% (down 107.0% YoY), and the FY2025 full-year result was 38.88%, up 189.0% from the prior year.
- Return on Capital Employed retreated to 38.9% in Q1 2026, from 35.4% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 19.03% in Q1 2022 to a low of 38.9% in Q1 2026.
- A 5-year average of 29.39% and a median of 29.28% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed sank 1686 bps in 2023 and jumped 438 bps in 2024, its largest moves.
- Tracing EWTX's Return on Capital Employed over 5 years: stood at 20.15% in 2022, then slumped by 84 bps to 37.02% in 2023, then gained by 10 bps to 33.42% in 2024, then declined by 6 bps to 35.4% in 2025, then decreased by 10 bps to 38.9% in 2026.
- Business Quant data shows EWTX's Return on Capital Employed at 38.9% in Q1 2026, 35.4% in Q4 2025, and 31.38% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Edgewise Therapeutics | 4.21 Bn | 4.21 Bn | - | -38.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.90% |
| Dec 31, 2025 | -35.40% |
| Sep 30, 2025 | -31.38% |
| Jun 30, 2025 | -34.03% |
| Mar 31, 2025 | -37.83% |
| Dec 31, 2024 | -33.42% |
| Sep 30, 2024 | -29.28% |
| Jun 30, 2024 | -25.91% |
| Mar 31, 2024 | -28.55% |
| Dec 31, 2023 | -37.02% |
| Sep 30, 2023 | -33.67% |
| Jun 30, 2023 | -28.20% |
| Mar 31, 2023 | -23.99% |
| Dec 31, 2022 | -20.15% |
| Sep 30, 2022 | -20.53% |
| Jun 30, 2022 | -22.36% |
| Mar 31, 2022 | -19.03% |
| Dec 31, 2021 | -15.47% |
| Sep 30, 2021 | -12.66% |
| Jun 30, 2021 | -9.08% |